ESLAWEstrella Immunopharma, Inc.同业对比
Estrella Immunopharma, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESLAW本股 | $3M#8 | — | — | — | — | — | — | — | — | — | 5.4%#1 | — |
| ZIVO | $5M#1 | — | — | 31.3x#5 | 468.6%#1 | -72.1%#9 | -8498.9%#3 | — | — | — | — | — |
| BKHAR | $4M#2 | — | — | — | — | -30.6%#8 | — | — | — | — | — | 1204.0%#1 |
| PMCB | $4M#3 | — | 0.2x#2 | — | — | -163.4%#11 | — | -70.6%#3 | -56.0%#1 | — | — | — |
| LIMNW | $4M#5 | — | 12.5x#6 | — | — | -187.8%#12 | — | -3395.2%#6 | -170.3%#3 | — | — | — |
| CLDI | $3M#7 | 0.0x#2 | 1.0x#5 | 68.9x#6 | — | 10.1%#6 | -44977.8%#7 | -635.4%#5 | — | — | — | — |
| BCAB | — | 0.1x#3 | — | — | — | -14.6%#7 | -19768.3%#6 | — | — | — | — | — |
| WINT | $3M#6 | — | — | 17.1x#3 | -88.9%#5 | 91.2%#3 | -13201.5%#5 | — | -308.7%#4 | — | — | 19.4%#2 |
| SABSW | $3M#9 | 0.1x#5 | 0.0x#1 | — | -100.0%#6 | 138.9%#1 | — | 6.2%#1 | — | — | — | — |
| CEROW | $3M#10 | — | — | — | — | — | — | — | — | — | — | 4.9%#3 |
| CRIS | $2M#11 | 0.1x#4 | 0.5x#4 | 0.3x#2 | -13.4%#3 | 82.5%#4 | -60.5%#1 | -161.5%#4 | -87.3%#2 | — | — | — |
| SLXN | $2M#12 | 0.0x#1 | 42.9x#7 | — | — | 27.9%#5 | — | -27072.7%#7 | — | — | — | — |
| SCLXW | $1M#13 | — | — | 0.0x#1 | -46.5%#4 | -413.8%#13 | -1143.7%#2 | — | — | 4#1 | — | — |
| VIVS | $4M#4 | — | — | 31.2x#4 | -9.0%#2 | -456.4%#14 | -8768.7%#4 | — | — | — | — | — |
| TVGNW | $312554#14 | — | — | — | — | -91.4%#10 | — | — | — | — | — | — |
| JSPRW | $296144#15 | — | 0.2x#3 | — | — | 100.0%#2 | — | -0.0%#2 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-15。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议